Serum (32-microgiobulin decreases in patients with aids or arc treated with azidothymidine

Mark A. Jacobson, Donald I. Abrams, Paul A. Volberding, Peter Bacchetti, Judith Wilber, Richard E Chaisson, Suzanne Crowe, Walter Howard, Andrew Moss

Research output: Contribution to journalArticle


Abnormally elevated serum p2-microglobulin has been associated with progression of human immunodeficiency virus (HIV) disease and could reflect in vivo HIV activity. We prospectively studied the effect of azidothymidine therapy on serum p2-microglobulin concentration in 41 patients with AIDS or AIDS-related complex. Median p2-microglobuIin concentration decreased from 4.02 mg/L before therapy to 3.73 mg/L at week 24 of therapy (P =.016). Individual changes in p2-microglobulin during azidothymidine therapy correlated with changes in serum HIV p24 antigen (Spearman, r =.42, P =.007). Also, in a randomized placebo-controlled study, median [)2-microglobulin concentration decreased after 16 w of therapy in 5 azidothymidine-treated patients compared with levels in 7 placebo-treated controls (P =.05). Serum p2-microglobulin appears to be a sensitive marker for in vivo antiretroviral drug activity and may be a better marker than serum p24 antigen for early intervention trials involving antiretroviral agents.

Original languageEnglish (US)
Pages (from-to)1029-1036
Number of pages8
JournalJournal of Infectious Diseases
Issue number6
Publication statusPublished - 1989
Externally publishedYes


ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Jacobson, M. A., Abrams, D. I., Volberding, P. A., Bacchetti, P., Wilber, J., Chaisson, R. E., ... Moss, A. (1989). Serum (32-microgiobulin decreases in patients with aids or arc treated with azidothymidine. Journal of Infectious Diseases, 159(6), 1029-1036.